Renalytix enters new collaboration with NYKHM
Renalytix announced a new collaboration with New York Kidney & Hypertension Medicine (NYKHM) on Tuesday, aimed at expanding access to its FDA-approved kidneyintelX.dkd test across underserved communities in the Greater New York area.
The AIM-traded firm said the partnership was expected to enable more than 2,000 patients with type-2 diabetes and early-to-mid-stage chronic kidney disease to benefit from the company’s prognostic blood testing.
NYKHM, a recognised leader in chronic kidney disease care, would integrate kidneyintelX.dkd into its clinical workflows to support personalised treatment strategies.
The test, which was also reimbursed by Medicare and recommended in international guidelines, uses blood-based biomarkers and machine learning to predict disease progression in stages 1 to 3b of CKD.
Renalytix said the initiative would focus on high-risk populations across Queens, Brooklyn, and the wider New York metropolitan area, aligning with Renalytix’s broader mission to improve early-stage kidney disease management through precision diagnostics.
In addition to test deployment, Renalytix and NYKHM would co-develop educational initiatives for community-based providers and launch public awareness campaigns to increase understanding of kidney disease risks and the benefits of early intervention.
“Dr Bhat and her team represent exactly the type of forward-thinking, patient-centered partners with whom we want to align,” said chief executive officer James McCullough.
“This partnership is a clear demonstration of how early prognosis, combined with community-based care, can shift the paradigm toward earlier detection and better outcomes in kidney disease.”
At 1133 BST, shares in Renalytix were up 3.45% at 7.5p.
Reporting by Josh White for Sharecast.com.